0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Topical Recombinant Thrombin Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-20Y17069
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Topical Recombinant Thrombin Market Research Report 2024
BUY CHAPTERS

Global Topical Recombinant Thrombin Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-20Y17069
Report
November 2025
Pages:158
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Topical Recombinant Thrombin Market

The global Topical Recombinant Thrombin market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Topical Recombinant Thrombin leading manufacturers including Takeda, Bayer, CSL, Grifols, GE Healthcare, Hualan Biological, Haematologic Technologies, Pfizer, Octapharma, Omrix Biopharmaceuticals, etc., dominate supply; the top five capture approximately % of global revenue, with Takeda leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Topical Recombinant Thrombin market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Topical Recombinant Thrombin Market Report

Report Metric Details
Report Name Topical Recombinant Thrombin Market
Segment by Type
  • Based Bovine
  • Based Human
  • Others
Segment by Application
  • Hospitals
  • Diagnostics & Clinics
  • Academic and Research Institute
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Takeda, Bayer, CSL, Grifols, GE Healthcare, Hualan Biological, Haematologic Technologies, Pfizer, Octapharma, Omrix Biopharmaceuticals, Shanghai RAAS
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Topical Recombinant Thrombin study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Topical Recombinant Thrombin Market report?

Ans: The main players in the Topical Recombinant Thrombin Market are Takeda, Bayer, CSL, Grifols, GE Healthcare, Hualan Biological, Haematologic Technologies, Pfizer, Octapharma, Omrix Biopharmaceuticals, Shanghai RAAS

What are the Application segmentation covered in the Topical Recombinant Thrombin Market report?

Ans: The Applications covered in the Topical Recombinant Thrombin Market report are Hospitals, Diagnostics & Clinics, Academic and Research Institute

What are the Type segmentation covered in the Topical Recombinant Thrombin Market report?

Ans: The Types covered in the Topical Recombinant Thrombin Market report are Based Bovine, Based Human, Others

1 Study Coverage
1.1 Introduction to Topical Recombinant Thrombin: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Topical Recombinant Thrombin Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Based Bovine
1.2.3 Based Human
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Topical Recombinant Thrombin Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Diagnostics & Clinics
1.3.4 Academic and Research Institute
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Topical Recombinant Thrombin Revenue Estimates and Forecasts 2020-2031
2.2 Global Topical Recombinant Thrombin Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Topical Recombinant Thrombin Sales Estimates and Forecasts 2020-2031
2.4 Global Topical Recombinant Thrombin Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Topical Recombinant Thrombin Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Topical Recombinant Thrombin Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Based Bovine Market Size by Manufacturers
3.5.2 Based Human Market Size by Manufacturers
3.5.3 Others Market Size by Manufacturers
3.6 Global Topical Recombinant Thrombin Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Topical Recombinant Thrombin Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Topical Recombinant Thrombin Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Topical Recombinant Thrombin Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Topical Recombinant Thrombin Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Topical Recombinant Thrombin Sales and Revenue by Type (2020-2031)
6.4 North America Topical Recombinant Thrombin Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Topical Recombinant Thrombin Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Topical Recombinant Thrombin Sales and Revenue by Type (2020-2031)
7.4 Europe Topical Recombinant Thrombin Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Topical Recombinant Thrombin Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Topical Recombinant Thrombin Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Topical Recombinant Thrombin Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Topical Recombinant Thrombin Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Topical Recombinant Thrombin Sales and Revenue by Type (2020-2031)
9.4 Central and South America Topical Recombinant Thrombin Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Topical Recombinant Thrombin Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Topical Recombinant Thrombin Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Topical Recombinant Thrombin Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Topical Recombinant Thrombin Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Takeda
11.1.1 Takeda Corporation Information
11.1.2 Takeda Business Overview
11.1.3 Takeda Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.1.4 Takeda Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Takeda Topical Recombinant Thrombin Sales by Product in 2024
11.1.6 Takeda Topical Recombinant Thrombin Sales by Application in 2024
11.1.7 Takeda Topical Recombinant Thrombin Sales by Geographic Area in 2024
11.1.8 Takeda Topical Recombinant Thrombin SWOT Analysis
11.1.9 Takeda Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Business Overview
11.2.3 Bayer Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.2.4 Bayer Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Bayer Topical Recombinant Thrombin Sales by Product in 2024
11.2.6 Bayer Topical Recombinant Thrombin Sales by Application in 2024
11.2.7 Bayer Topical Recombinant Thrombin Sales by Geographic Area in 2024
11.2.8 Bayer Topical Recombinant Thrombin SWOT Analysis
11.2.9 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Corporation Information
11.3.2 CSL Business Overview
11.3.3 CSL Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.3.4 CSL Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 CSL Topical Recombinant Thrombin Sales by Product in 2024
11.3.6 CSL Topical Recombinant Thrombin Sales by Application in 2024
11.3.7 CSL Topical Recombinant Thrombin Sales by Geographic Area in 2024
11.3.8 CSL Topical Recombinant Thrombin SWOT Analysis
11.3.9 CSL Recent Developments
11.4 Grifols
11.4.1 Grifols Corporation Information
11.4.2 Grifols Business Overview
11.4.3 Grifols Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.4.4 Grifols Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Grifols Topical Recombinant Thrombin Sales by Product in 2024
11.4.6 Grifols Topical Recombinant Thrombin Sales by Application in 2024
11.4.7 Grifols Topical Recombinant Thrombin Sales by Geographic Area in 2024
11.4.8 Grifols Topical Recombinant Thrombin SWOT Analysis
11.4.9 Grifols Recent Developments
11.5 GE Healthcare
11.5.1 GE Healthcare Corporation Information
11.5.2 GE Healthcare Business Overview
11.5.3 GE Healthcare Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.5.4 GE Healthcare Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 GE Healthcare Topical Recombinant Thrombin Sales by Product in 2024
11.5.6 GE Healthcare Topical Recombinant Thrombin Sales by Application in 2024
11.5.7 GE Healthcare Topical Recombinant Thrombin Sales by Geographic Area in 2024
11.5.8 GE Healthcare Topical Recombinant Thrombin SWOT Analysis
11.5.9 GE Healthcare Recent Developments
11.6 Hualan Biological
11.6.1 Hualan Biological Corporation Information
11.6.2 Hualan Biological Business Overview
11.6.3 Hualan Biological Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.6.4 Hualan Biological Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Hualan Biological Recent Developments
11.7 Haematologic Technologies
11.7.1 Haematologic Technologies Corporation Information
11.7.2 Haematologic Technologies Business Overview
11.7.3 Haematologic Technologies Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.7.4 Haematologic Technologies Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Haematologic Technologies Recent Developments
11.8 Pfizer
11.8.1 Pfizer Corporation Information
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.8.4 Pfizer Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Pfizer Recent Developments
11.9 Octapharma
11.9.1 Octapharma Corporation Information
11.9.2 Octapharma Business Overview
11.9.3 Octapharma Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.9.4 Octapharma Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Octapharma Recent Developments
11.10 Omrix Biopharmaceuticals
11.10.1 Omrix Biopharmaceuticals Corporation Information
11.10.2 Omrix Biopharmaceuticals Business Overview
11.10.3 Omrix Biopharmaceuticals Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.10.4 Omrix Biopharmaceuticals Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Omrix Biopharmaceuticals Recent Developments
11.11 Shanghai RAAS
11.11.1 Shanghai RAAS Corporation Information
11.11.2 Shanghai RAAS Business Overview
11.11.3 Shanghai RAAS Topical Recombinant Thrombin Product Models, Descriptions and Specifications
11.11.4 Shanghai RAAS Topical Recombinant Thrombin Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Shanghai RAAS Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Topical Recombinant Thrombin Industry Chain
12.2 Topical Recombinant Thrombin Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Topical Recombinant Thrombin Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Topical Recombinant Thrombin Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Topical Recombinant Thrombin Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Topical Recombinant Thrombin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Topical Recombinant Thrombin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Topical Recombinant Thrombin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Topical Recombinant Thrombin Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Topical Recombinant Thrombin Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Topical Recombinant Thrombin Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Topical Recombinant Thrombin Sales by Region (2020-2025) & (K Units)
 Table 8. Global Topical Recombinant Thrombin Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Topical Recombinant Thrombin Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Topical Recombinant Thrombin Sales Share by Manufacturers (2020-2025)
 Table 12. Global Topical Recombinant Thrombin Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Topical Recombinant Thrombin Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Topical Recombinant Thrombin by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Topical Recombinant Thrombin as of 2024)
 Table 16. Global Topical Recombinant Thrombin Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Topical Recombinant Thrombin Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Topical Recombinant Thrombin Manufacturing Base and Headquarters
 Table 19. Global Topical Recombinant Thrombin Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Topical Recombinant Thrombin Sales by Type (2020-2025) & (K Units)
 Table 23. Global Topical Recombinant Thrombin Sales by Type (2026-2031) & (K Units)
 Table 24. Global Topical Recombinant Thrombin Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Topical Recombinant Thrombin Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Topical Recombinant Thrombin ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Topical Recombinant Thrombin Sales by Application (2020-2025) & (K Units)
 Table 29. Global Topical Recombinant Thrombin Sales by Application (2026-2031) & (K Units)
 Table 30. Topical Recombinant Thrombin High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Topical Recombinant Thrombin Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Topical Recombinant Thrombin Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Topical Recombinant Thrombin ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Topical Recombinant Thrombin Growth Accelerators and Market Barriers
 Table 37. North America Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Topical Recombinant Thrombin Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Topical Recombinant Thrombin Growth Accelerators and Market Barriers
 Table 40. Europe Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Topical Recombinant Thrombin Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Topical Recombinant Thrombin Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Topical Recombinant Thrombin Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Topical Recombinant Thrombin Investment Opportunities and Key Challenges
 Table 47. Central and South America Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Topical Recombinant Thrombin Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Topical Recombinant Thrombin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Takeda Corporation Information
 Table 51. Takeda Description and Major Businesses
 Table 52. Takeda Product Models, Descriptions and Specifications
 Table 53. Takeda Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Takeda Sales Value Proportion by Product in 2024
 Table 55. Takeda Sales Value Proportion by Application in 2024
 Table 56. Takeda Sales Value Proportion by Geographic Area in 2024
 Table 57. Takeda Topical Recombinant Thrombin SWOT Analysis
 Table 58. Takeda Recent Developments
 Table 59. Bayer Corporation Information
 Table 60. Bayer Description and Major Businesses
 Table 61. Bayer Product Models, Descriptions and Specifications
 Table 62. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Bayer Sales Value Proportion by Product in 2024
 Table 64. Bayer Sales Value Proportion by Application in 2024
 Table 65. Bayer Sales Value Proportion by Geographic Area in 2024
 Table 66. Bayer Topical Recombinant Thrombin SWOT Analysis
 Table 67. Bayer Recent Developments
 Table 68. CSL Corporation Information
 Table 69. CSL Description and Major Businesses
 Table 70. CSL Product Models, Descriptions and Specifications
 Table 71. CSL Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. CSL Sales Value Proportion by Product in 2024
 Table 73. CSL Sales Value Proportion by Application in 2024
 Table 74. CSL Sales Value Proportion by Geographic Area in 2024
 Table 75. CSL Topical Recombinant Thrombin SWOT Analysis
 Table 76. CSL Recent Developments
 Table 77. Grifols Corporation Information
 Table 78. Grifols Description and Major Businesses
 Table 79. Grifols Product Models, Descriptions and Specifications
 Table 80. Grifols Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Grifols Sales Value Proportion by Product in 2024
 Table 82. Grifols Sales Value Proportion by Application in 2024
 Table 83. Grifols Sales Value Proportion by Geographic Area in 2024
 Table 84. Grifols Topical Recombinant Thrombin SWOT Analysis
 Table 85. Grifols Recent Developments
 Table 86. GE Healthcare Corporation Information
 Table 87. GE Healthcare Description and Major Businesses
 Table 88. GE Healthcare Product Models, Descriptions and Specifications
 Table 89. GE Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. GE Healthcare Sales Value Proportion by Product in 2024
 Table 91. GE Healthcare Sales Value Proportion by Application in 2024
 Table 92. GE Healthcare Sales Value Proportion by Geographic Area in 2024
 Table 93. GE Healthcare Topical Recombinant Thrombin SWOT Analysis
 Table 94. GE Healthcare Recent Developments
 Table 95. Hualan Biological Corporation Information
 Table 96. Hualan Biological Description and Major Businesses
 Table 97. Hualan Biological Product Models, Descriptions and Specifications
 Table 98. Hualan Biological Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Hualan Biological Recent Developments
 Table 100. Haematologic Technologies Corporation Information
 Table 101. Haematologic Technologies Description and Major Businesses
 Table 102. Haematologic Technologies Product Models, Descriptions and Specifications
 Table 103. Haematologic Technologies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Haematologic Technologies Recent Developments
 Table 105. Pfizer Corporation Information
 Table 106. Pfizer Description and Major Businesses
 Table 107. Pfizer Product Models, Descriptions and Specifications
 Table 108. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Pfizer Recent Developments
 Table 110. Octapharma Corporation Information
 Table 111. Octapharma Description and Major Businesses
 Table 112. Octapharma Product Models, Descriptions and Specifications
 Table 113. Octapharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Octapharma Recent Developments
 Table 115. Omrix Biopharmaceuticals Corporation Information
 Table 116. Omrix Biopharmaceuticals Description and Major Businesses
 Table 117. Omrix Biopharmaceuticals Product Models, Descriptions and Specifications
 Table 118. Omrix Biopharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Omrix Biopharmaceuticals Recent Developments
 Table 120. Shanghai RAAS Corporation Information
 Table 121. Shanghai RAAS Description and Major Businesses
 Table 122. Shanghai RAAS Product Models, Descriptions and Specifications
 Table 123. Shanghai RAAS Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Shanghai RAAS Recent Developments
 Table 125. Key Raw Materials Distribution
 Table 126. Raw Materials Key Suppliers
 Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 128. Milestones in Production Technology Evolution
 Table 129. Distributors List
 Table 130. Market Trends and Market Evolution
 Table 131. Market Drivers and Opportunities
 Table 132. Market Challenges, Risks, and Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources


List of Figures
 Figure 1. Topical Recombinant Thrombin Product Picture
 Figure 2. Global Topical Recombinant Thrombin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Based Bovine Product Picture
 Figure 4. Based Human Product Picture
 Figure 5. Others Product Picture
 Figure 6. Global Topical Recombinant Thrombin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Hospitals
 Figure 8. Diagnostics & Clinics
 Figure 9. Academic and Research Institute
 Figure 10. Topical Recombinant Thrombin Report Years Considered
 Figure 11. Global Topical Recombinant Thrombin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Topical Recombinant Thrombin Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Topical Recombinant Thrombin Revenue Market Share by Region (2020-2031)
 Figure 15. Global Topical Recombinant Thrombin Sales (2020-2031) & (K Units)
 Figure 16. Global Topical Recombinant Thrombin Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 17. Global Topical Recombinant Thrombin Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers Topical Recombinant Thrombin Sales Volume Market Share in 2024
 Figure 19. Global Topical Recombinant Thrombin Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Based Bovine Revenue Market Share by Manufacturer in 2024
 Figure 22. Based Human Revenue Market Share by Manufacturer in 2024
 Figure 23. Others Revenue Market Share by Manufacturer in 2024
 Figure 24. Global Topical Recombinant Thrombin Sales Market Share by Type (2020-2031)
 Figure 25. Global Topical Recombinant Thrombin Revenue Market Share by Type (2020-2031)
 Figure 26. Global Topical Recombinant Thrombin Sales Market Share by Application (2020-2031)
 Figure 27. Global Topical Recombinant Thrombin Revenue Market Share by Application (2020-2031)
 Figure 28. North America Topical Recombinant Thrombin Sales YoY (2020-2031) & (K Units)
 Figure 29. North America Topical Recombinant Thrombin Revenue YoY (2020-2031) & (US$ Million)
 Figure 30. North America Top 5 Manufacturers Topical Recombinant Thrombin Sales Revenue (US$ Million) in 2024
 Figure 31. North America Topical Recombinant Thrombin Sales Volume (K Units) by Type (2020- 2031)
 Figure 32. North America Topical Recombinant Thrombin Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 33. North America Topical Recombinant Thrombin Sales Volume (K Units) by Application (2020-2031)
 Figure 34. North America Topical Recombinant Thrombin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 35. US Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 36. Canada Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 37. Mexico Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 38. Europe Topical Recombinant Thrombin Sales YoY (2020-2031) & (K Units)
 Figure 39. Europe Topical Recombinant Thrombin Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Europe Top 5 Manufacturers Topical Recombinant Thrombin Sales Revenue (US$ Million) in 2024
 Figure 41. Europe Topical Recombinant Thrombin Sales Volume (K Units) by Type (2020-2031)
 Figure 42. Europe Topical Recombinant Thrombin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 43. Europe Topical Recombinant Thrombin Sales Volume (K Units) by Application (2020-2031)
 Figure 44. Europe Topical Recombinant Thrombin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 45. Germany Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 46. France Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 47. U.K. Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 48. Italy Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 49. Russia Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Topical Recombinant Thrombin Sales YoY (2020-2031) & (K Units)
 Figure 51. Asia-Pacific Topical Recombinant Thrombin Revenue YoY (2020-2031) & (US$ Million)
 Figure 52. Asia-Pacific Top 8 Manufacturers Topical Recombinant Thrombin Sales Revenue (US$ Million) in 2024
 Figure 53. Asia-Pacific Topical Recombinant Thrombin Sales Volume (K Units) by Type (2020- 2031)
 Figure 54. Asia-Pacific Topical Recombinant Thrombin Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 55. Asia-Pacific Topical Recombinant Thrombin Sales Volume (K Units) by Application (2020-2031)
 Figure 56. Asia-Pacific Topical Recombinant Thrombin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Indonesia Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 58. Japan Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 59. South Korea Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 60. China Taiwan Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 61. India Topical Recombinant Thrombin Revenue (2020-2031) & (US$ Million)
 Figure 62. Central and South America Topical Recombinant Thrombin Sales YoY (2020-2031) & (K Units)
 Figure 63. Central and South America Topical Recombinant Thrombin Revenue YoY (2020-2031) & (US$ Million)
 Figure 64. Central and South America Top 5 Manufacturers Topical Recombinant Thrombin Sales Revenue (US$ Million) in 2024
 Figure 65. Central and South America Topical Recombinant Thrombin Sales Volume (K Units) by Type (2021-2031)
 Figure 66. Central and South America Topical Recombinant Thrombin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 67. Central and South America Topical Recombinant Thrombin Sales Volume (K Units) by Application (2020-2031)
 Figure 68. Central and South America Topical Recombinant Thrombin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 69. Brazil Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 70. Argentina Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 71. Middle East, and Africa Topical Recombinant Thrombin Sales YoY (2020-2031) & (K Units)
 Figure 72. Middle East and Africa Topical Recombinant Thrombin Revenue YoY (2020-2031) & (US$ Million)
 Figure 73. Middle East and Africa Top 5 Manufacturers Topical Recombinant Thrombin Sales Revenue (US$ Million) in 2024
 Figure 74. Middle East and Africa Topical Recombinant Thrombin Sales Volume (K Units) by Type (2021-2031)
 Figure 75. South America Topical Recombinant Thrombin Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 76. Middle East and Africa Topical Recombinant Thrombin Sales Volume (K Units) by Application (2020-2031)
 Figure 77. Middle East and Africa Topical Recombinant Thrombin Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 78. GCC Countries Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 79. Turkey Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 80. Egypt Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 81. South Africa Topical Recombinant Thrombin Revenue (2020-2025) & (US$ Million)
 Figure 82. Topical Recombinant Thrombin Industry Chain Mapping
 Figure 83. Regional Topical Recombinant Thrombin Manufacturing Base Distribution (%)
 Figure 84. Global Topical Recombinant Thrombin Production Market Share by Region (2020-2031)
 Figure 85. Topical Recombinant Thrombin Production Process
 Figure 86. Regional Topical Recombinant Thrombin Production Cost Structure
 Figure 87. Channels of Distribution (Direct Vs Distribution)
 Figure 88. Bottom-up and Top-down Approaches for This Report
 Figure 89. Data Triangulation
 Figure 90. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension